Bruce Neal's Publications

About Bruce Neal's Publications

Executive Director, The George Institute for Global Health, Australia

  • The performance and potential of the Australasian Health Star Rating system: a four-year review using the RE-AIM framework

    Australian and New Zealand Journal of Public Health Date published:

  • Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

    Circulation Date published:

  • Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program

    Diabetologia Date published:

  • Outcome Assessment by Central Adjudicators Versus Site Investigators in Stroke Trials

    Stroke Date published:

  • The Healthfulness of the US Packaged Food and Beverage Supply: A Cross-Sectional Study

    Nutrients Date published:

  • A comparison of the healthiness of packaged foods and beverages from 12 countries using the Health Star Rating nutrient profiling system, 2013-2018

    Obesity Reviews Date published:

  • Dietary Sodium Reduction Reduces Albuminuria: A Cluster Randomized Trial

    Journal of Renal Nutrition Date published:

  • Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease

    Kidney International Date published:

  • Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

    New England Journal of Medicine Date published:

  • Impact of Salt Substitute and Stepwise Reduction of Salt Supply on Blood Pressure in the Elderly in Nursing Homes (DECIDE-Salt Trial): Protocol and Baseline Characteristics

    Nutrition Date published:

  • Impact of Salt Substitute and Stepwise Reduction of Salt Supply on Blood Pressure in the Elderly in Nursing Homes (DECIDE-Salt Trial): Protocol and Baseline Characteristics (P13-022-19)

    Current Developments in Nutrition Date published:

  • 1203-P: Cause of Hospitalizations in Patients with Type 2 Diabetes Mellitus (T2DM) in the CANVAS Program

    Diabetes Date published:

  • 1216-P: The Effects of Canagliflozin on Uric Acid and Gout in Patients with Type 2 Diabetes in the CANVAS Program

    Diabetes Date published:

  • 1206-P: Effects of Canagliflozin (CANA) on Initiation of Insulin in CANVAS Program

    Diabetes Date published:

  • FP484DIFFERENT eGFR THRESHOLDS AND THE RENAL EFFECTS OF CANAGLIFLOZIN: DATA FROM THE CANVAS PROGRAM

    Nephrology Dialysis Transplantation Date published:

  • Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus

    Circulation Date published: